Integrating the patient's perspective into device evaluation trials

被引:14
作者
Leidy, Nancy Kline
Beusterien, Kathleen
Sullivan, Erin
Richner, Randel
Muni, Neal I.
机构
[1] United BioSource Corp, Ctr Hlth Outcomes Res, Bethesda, MD 20814 USA
[2] Boston Sci, Boston, MA USA
[3] US FDA, Rockville, MD 20857 USA
关键词
device; patient-reported outcomes; quality of life;
D O I
10.1111/j.1524-4733.2006.00132.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Innovations in medical device technology have greatly expanded the range of therapeutic options available to physicians and their patients. The understanding of treatment effects from the patient's perspective is an essential component of a comprehensive assessment of any new therapy, including medical devices. The term "patient-reported outcomes" (PROs) has been growing in use to refer to a cluster of variables such as health-related quality of life, symptoms, physical functioning, psychological well-being, treatment satisfaction, and treatment preferences. As in drug trials, the use of PROs in device evaluation has several methodological challenges, ranging from general concerns about interpretation, to more specific issues related to study design and regulatory approval (use of PROs as primary end points, incorporation in labeling, and product promotion). Successful approaches for integrating PROs into device evaluation trials include the careful selection of appropriate, interpretable PRO end points, accounting for possible confounding factors, and the use of alternatives to placebo-controlled trial designs, such as single-arm pre-post, observational, and registry studies, when the use of placebo control groups is not feasible. This article discusses the potential value and difficulties in measuring PROs in device studies.
引用
收藏
页码:394 / 401
页数:8
相关论文
共 30 条
[1]   Incorporating the patient's perspective into drug development and communication: An ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the Food and Drug Administration, February 16, 2001 [J].
Acquadro, C ;
Berzon, R ;
Dubois, D ;
Leidy, NK ;
Marquis, P ;
Revicki, D ;
Rothman, M .
VALUE IN HEALTH, 2003, 6 (05) :522-531
[2]   Development of cardiovascular drugs - The US regulatory milieu from the perspective of a participating nonregulator [J].
Borer, JS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (12) :2285-2292
[3]  
Buckman P M, 1989, J Spinal Disord, V2, P292
[4]   Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device [J].
Burkus, JK ;
Heim, TE ;
Gornet, MF ;
Zdeblick, TA .
JOURNAL OF SPINAL DISORDERS & TECHNIQUES, 2003, 16 (02) :113-122
[5]   Cost effectiveness of complementary treatments in the United Kingdom: systematic review [J].
Canter, PH ;
Coon, JT ;
Ernst, E .
BRITISH MEDICAL JOURNAL, 2005, 331 (7521) :880-881
[6]   An Internet-based store-and-forward video home telehealth system for improving asthma outcomes in children [J].
Chan, DS ;
Callahan, CW ;
Sheets, SJ ;
Moreno, CN ;
Malone, FJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (19) :1976-1981
[7]  
Chen L, 1999, AM J MANAG CARE, V5, P899
[8]   Clinical experience with the low pressure Novus valve in the treatment of adult hydrocephalus [J].
Chong, CCW ;
van Gelder, J ;
Sheridan, M .
JOURNAL OF CLINICAL NEUROSCIENCE, 2002, 9 (05) :539-543
[9]   VENTRICULAR-FIBRILLATION, AUTOMATIC EXTERNAL DEFIBRILLATORS, AND THE UNITED-STATES FOOD-AND-DRUG-ADMINISTRATION - CONFRONTATION WITHOUT COMPREHENSION [J].
CUMMINS, RO ;
WHITE, RD ;
PEPE, PE .
ANNALS OF EMERGENCY MEDICINE, 1995, 26 (05) :621-631
[10]  
CUMMINS RO, 1995, ANN EMERG MED, V26, P32